Vaxcyte (NASDAQ: PCVX) director receives RSU and stock option grants
Rhea-AI Filing Summary
Vaxcyte, Inc. director Teri Loxam reported receiving equity-based compensation. The filing shows a grant of 2,265 shares of Common Stock underlying restricted stock units (RSUs) and a separate grant of stock options covering 11,389 shares of Common Stock.
The RSUs vest in full on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to continuous service, and delivery has been deferred under the company’s Nonqualified RSU Deferral Program for Non-Employee Directors. The stock options have an exercise price of $49.56 per share, vest monthly on the same schedule, and expire on June 15, 2036. Following the RSU grant, Loxam directly holds 12,481 shares of Common Stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 2,265 shares
Net Buy
2 txns
Insider
Loxam Teri
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 11,389 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 2,265 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 11,389 shares (Direct);
Common Stock — 12,481 shares (Direct)
Footnotes (2)
- F1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control .
- F2. The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Key Figures
RSU grant: 2,265 shares
Option grant size: 11,389 shares
Option exercise price: $49.56/share
+2 more
5 metrics
RSU grant
2,265 shares
Common Stock underlying RSUs granted to director
Option grant size
11,389 shares
Stock options for Common Stock granted to director
Option exercise price
$49.56/share
Exercise price for granted stock options
Option expiration
June 15, 2036
Expiration date of stock options
Shares held after grant
12,481 shares
Common Stock directly held after RSU grant
Key Terms
restricted stock units ("RSUs"), Nonqualified RSU Deferral Program for Non-Employee Directors, separation from service, qualifying change in control, +1 more
5 terms
restricted stock units ("RSUs") financial
"Represents the number of shares of Common Stock underlying restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Nonqualified RSU Deferral Program for Non-Employee Directors financial
"Pursuant to the Issuer's Nonqualified RSU Deferral Program for Non-Employee Directors, the Reporting Person has deferred delivery..."
separation from service financial
"deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control"
qualifying change in control financial
"deferred delivery of all of such vested RSUs to the earlier of (i) a separation from service, or (ii) a qualifying change in control"
Stock Option (right to buy) financial
"The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027..."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Vaxcyte (PCVX) director Teri Loxam report?
Teri Loxam reported receiving equity compensation grants, not open-market trades. The filing shows new RSUs tied to Common Stock and a separate stock option grant, both contingent on continued board service and standard vesting conditions.
How many Vaxcyte (PCVX) RSUs did Teri Loxam receive in this Form 4?
The filing shows 2,265 shares of Vaxcyte Common Stock underlying restricted stock units. Each RSU represents a contingent right to one share, vesting in full on a future date tied to board service and the company’s annual meeting schedule.
What stock options were granted to Teri Loxam by Vaxcyte (PCVX)?
Loxam received stock options for 11,389 shares of Vaxcyte Common Stock at an exercise price of $49.56 per share. These options vest monthly and are scheduled to be fully vested by June 15, 2027, subject to continuous service.
When do Teri Loxam’s Vaxcyte (PCVX) RSUs and options vest?
Both the RSUs and options will fully vest on the earlier of June 15, 2027 or the day before Vaxcyte’s next annual stockholder meeting. Vesting is subject to acceleration provisions and Loxam’s continuous service as described in the filing footnotes.
What is the deferral arrangement for Teri Loxam’s Vaxcyte (PCVX) RSUs?
Under Vaxcyte’s Nonqualified RSU Deferral Program for Non-Employee Directors, Loxam has deferred delivery of all vested RSUs. Shares will be delivered at the earlier of a separation from service or a qualifying change in control, according to the footnote.